{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:14:26Z","timestamp":1788423266277,"version":"build-2803163510"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Cape Town"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiovascular disease remains the leading cause of death worldwide, imposing significant morbidity and healthcare costs. While low serum high-density lipoprotein (HDL)-cholesterol levels have traditionally been linked to cardiovascular risk, most pharmacological interventions aimed at raising HDL-cholesterol levels have not consistently improved cardiovascular outcomes. Epidemiologic and genetic studies further suggest that circulating HDL-cholesterol levels may not directly determine cardiovascular risk, underscoring the complexity of HDL particles in cardiovascular health. HDL particles are dynamic, multifunctional complexes composed of diverse proteins and lipids, whose composition determines their cardioprotective properties. In cardiovascular disease, the composition of HDL particles is frequently remodeled, resulting in dysfunctional particles with impaired antioxidant, anti-inflammatory, and lipid transport functions. Consequently, the composition and functionality of HDL particles, rather than their cholesterol content, appear to be the primary determinants of their protective capacity. A deeper understanding of HDL particles\u2019 compositional changes in cardiovascular disease may guide therapies that restore their protective capacity, thus offering a more effective strategy to reduce cardiovascular risk. This review summarizes current knowledge on changes in the proteomic and lipidomic composition of HDL particles associated with cardiovascular disease, highlighting molecular alterations that may drive HDL particle dysfunction.<\/jats:p>","DOI":"10.1007\/s10557-026-07949-5","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:41:12Z","timestamp":1788421272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Profiling Cardiovascular Disease-Associated Changes in the Composition of High-Density Lipoprotein Particles"],"prefix":"10.1007","author":[{"given":"Tanith","family":"Fester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5991-4921","authenticated-orcid":false,"given":"Carmelita","family":"Abrahams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-8974","authenticated-orcid":false,"given":"Sandrine","family":"Lecour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"25","key":"7949_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022;80(25):2361\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.005.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7949_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/01.atv.8.6.737","volume":"8","author":"PW Wilson","year":"1988","unstructured":"Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arterioscler Thromb Vasc Biol. 1988;8(6):737\u201341. https:\/\/doi.org\/10.1161\/01.atv.8.6.737.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"16","key":"7949_CR3","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2023","unstructured":"von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2023;44(16):1394\u2013407. https:\/\/doi.org\/10.1093\/eurheartj\/ehac605.","journal-title":"Eur Heart J"},{"issue":"9841","key":"7949_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/s0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(12)60312-2.","journal-title":"Lancet"},{"issue":"9","key":"7949_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","volume":"36","author":"MV Holmes","year":"2015","unstructured":"Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/eht571.","journal-title":"Eur Heart J"},{"issue":"7","key":"7949_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamacardio.2022.0912","volume":"7","author":"C Liu","year":"2022","unstructured":"Liu C, Dhindsa D, Almuwaqqat Z, et al. Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. JAMA Cardiol. 2022;7(7):672\u201380. https:\/\/doi.org\/10.1001\/jamacardio.2022.0912.","journal-title":"JAMA Cardiol"},{"key":"7949_CR7","doi-asserted-by":"publisher","unstructured":"Sherly AA, Mysore Srikantiah R, Rohatgi A, et al. High Density Lipoprotein Assessment Revisited: A Review of Foundational Understanding and Recent Developments in Function, Particle Size, and Cardiometabolic Impact. Curr Atheroscler Rep. 2026;28:42. https:\/\/doi.org\/10.1007\/s11883-026-01413-3.","DOI":"10.1007\/s11883-026-01413-3"},{"issue":"13","key":"7949_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/CIRCULATIONAHA.105.607135","volume":"114","author":"G Theilmeier","year":"2006","unstructured":"Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia\/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006;114(13):1403\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.607135.","journal-title":"Circulation"},{"issue":"9","key":"7949_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.lfs.2007.06.021","volume":"81","author":"S-s Gu","year":"2007","unstructured":"Gu S-s, Shi N, Wu M-p. The protective effect of ApolipoproteinA-I on myocardial ischemia\u2013reperfusion injury in rats. Life Sci. 2007;81(9):702\u20139. https:\/\/doi.org\/10.1016\/j.lfs.2007.06.021.","journal-title":"Life Sci"},{"issue":"1","key":"7949_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/cvr\/cvp289","volume":"85","author":"MA Frias","year":"2010","unstructured":"Frias MA, Lang U, Gerber-Wicht C, James RW. Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc Res. 2010;85(1):118\u201326. https:\/\/doi.org\/10.1093\/cvr\/cvp289.","journal-title":"Cardiovasc Res"},{"key":"7949_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2018.12.002","volume":"281","author":"AA Soares","year":"2019","unstructured":"Soares AA, Carvalho LSF, Bonilha I, et al. Adverse interaction between HDL and the mass of myocardial infarction. Atherosclerosis. 2019;281:9\u201316. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.12.002.","journal-title":"Atherosclerosis"},{"issue":"2","key":"7949_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.atherosclerosis.2014.10.103","volume":"237","author":"LSF Carvalho","year":"2014","unstructured":"Carvalho LSF, Panzoldo N, Santos SN, et al. HDL levels and oxidizability during myocardial infarction are associated with reduced endothelial-mediated vasodilation and nitric oxide bioavailability. Atherosclerosis. 2014;237(2):840\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.10.103.","journal-title":"Atherosclerosis"},{"issue":"6","key":"7949_CR13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jacl.2016.08.003","volume":"10","author":"W Annema","year":"2016","unstructured":"Annema W, Willemsen HM, de Boer JF, et al. HDL function is impaired in acute myocardial infarction independent of plasma HDL cholesterol levels. J Clin Lipidol. 2016;10(6):1318\u201328. https:\/\/doi.org\/10.1016\/j.jacl.2016.08.003.","journal-title":"J Clin Lipidol"},{"key":"7949_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cca.2014.02.026","volume":"433","author":"RP Dullaart","year":"2014","unstructured":"Dullaart RP, Annema W, Tio RA, Tietge UJ. The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol. Clin Chim Acta. 2014;433:34\u20138. https:\/\/doi.org\/10.1016\/j.cca.2014.02.026.","journal-title":"Clin Chim Acta"},{"issue":"8","key":"7949_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/circulationaha.112.108753","volume":"127","author":"M Riwanto","year":"2013","unstructured":"Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti-and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein\u2013proteome remodeling. Circulation. 2013;127(8):891\u2013904. https:\/\/doi.org\/10.1161\/circulationaha.112.108753.","journal-title":"Circulation"},{"issue":"4","key":"7949_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2022.159119","volume":"1867","author":"KL Ong","year":"2022","unstructured":"Ong KL, Cochran BJ, Manandhar B, Thomas S, Rye KA. HDL maturation and remodelling. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(4):159119. https:\/\/doi.org\/10.1016\/j.bbalip.2022.159119.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"2","key":"7949_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2021.159072","volume":"1867","author":"WS Davidson","year":"2022","unstructured":"Davidson WS, Shah AS, Sexmith H, Gordon SM. The HDL proteome watch: compilation of studies leads to new insights on HDL function. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(2):159072. https:\/\/doi.org\/10.1016\/j.bbalip.2021.159072.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"11","key":"7949_CR18","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1194\/jlr.r036095","volume":"54","author":"A Kontush","year":"2013","unstructured":"Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res. 2013;54(11):2950\u201363. https:\/\/doi.org\/10.1194\/jlr.r036095.","journal-title":"J Lipid Res"},{"issue":"7","key":"7949_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00930-7","volume":"23","author":"KC Vickers","year":"2021","unstructured":"Vickers KC, Michell DL. HDL-small RNA export, transport, and functional delivery in atherosclerosis. Curr Atheroscler Rep. 2021;23(7):38. https:\/\/doi.org\/10.1007\/s11883-021-00930-7.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"7949_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdnut.2025.107499","volume":"9","author":"JD Bean","year":"2025","unstructured":"Bean JD, Peterson CA. A hitchhiker story? Exploring HDL as an overlooked vitamin D carrier. Curr Dev Nutr. 2025;107499. https:\/\/doi.org\/10.1016\/j.cdnut.2025.107499.","journal-title":"Curr Dev Nutr"},{"issue":"7\u20138","key":"7949_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/s0891-5849(99)00139-2","volume":"27","author":"I Kolleck","year":"1999","unstructured":"Kolleck I, Schlame M, Fechner H, et al. HDL is the major source of vitamin E for type II pneumocytes. Free Radic Biol Med. 1999;27(7\u20138):882\u201390. https:\/\/doi.org\/10.1016\/s0891-5849(99)00139-2.","journal-title":"Free Radic Biol Med"},{"key":"7949_CR22","doi-asserted-by":"publisher","first-page":"109111","DOI":"10.1016\/j.abb.2021.109111","volume":"716","author":"B Li","year":"2022","unstructured":"Li B, Vachali P, Chang F-Y, et al. HDL is the primary transporter for carotenoids from liver to retinal pigment epithelium in transgenic ApoA-I\u2013\/\u2013\/Bco2\u2013\/\u2013 mice. Arch Biochem Biophys. 2022;716:109111. https:\/\/doi.org\/10.1016\/j.abb.2021.109111.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"7949_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1373\/clinchem.2016.257725","volume":"63","author":"SK Karathanasis","year":"2017","unstructured":"Karathanasis SK, Freeman LA, Gordon SM, Remaley AT. The changing face of HDL and the best way to measure it. Clin Chem. 2017;63(1):196\u2013210. https:\/\/doi.org\/10.1373\/clinchem.2016.257725.","journal-title":"Clin Chem"},{"issue":"12","key":"7949_CR24","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1161\/01.res.0000170946.56981.5c","volume":"96","author":"GF Lewis","year":"2005","unstructured":"Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221\u201332. https:\/\/doi.org\/10.1161\/01.res.0000170946.56981.5c.","journal-title":"Circ Res"},{"key":"7949_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fcvm.2020.00039","volume":"7","author":"A Jomard","year":"2020","unstructured":"Jomard A, Osto E. High density lipoproteins: metabolism, function, and therapeutic potential. Front Cardiovasc Med. 2020;7:39. https:\/\/doi.org\/10.3389\/fcvm.2020.00039.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"7949_CR26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","volume":"17","author":"L Camont","year":"2011","unstructured":"Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17(10):594\u2013603. https:\/\/doi.org\/10.1016\/j.molmed.2011.05.013.","journal-title":"Trends Mol Med"},{"key":"7949_CR27","volume-title":"Handb Exp Pharmacol","author":"VI Zannis","year":"2015","unstructured":"Zannis VI, Fotakis P, Koukos G. HDL biogenesis, remodeling, and catabolism. In: Handb Exp Pharmacol. Cham, Heidelberg, New York, Dorcrecht and London: Springer; 2015."},{"issue":"11","key":"7949_CR28","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.bbalip.2013.07.014","volume":"1831","author":"C R\u00f6hrl","year":"2013","unstructured":"R\u00f6hrl C, Stangl H. HDL endocytosis and resecretion. Biochim Biophys Acta Mol Cell Biol Lipids. 2013;1831(11):1626\u201333. https:\/\/doi.org\/10.1016\/j.bbalip.2013.07.014.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"7949_CR29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3389\/fphar.2017.00989","volume":"8","author":"NJ Woudberg","year":"2018","unstructured":"Woudberg NJ, Pedretti S, Lecour S, et al. Pharmacological intervention to modulate HDL: what do we target? Front Pharmacol. 2018;8:989. https:\/\/doi.org\/10.3389\/fphar.2017.00989.","journal-title":"Front Pharmacol"},{"issue":"2","key":"7949_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4161\/jkst.19754","volume":"1","author":"MA Frias","year":"2012","unstructured":"Frias MA, Lecour S, James RW, Pedretti S. High density lipoprotein\/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. Jakstat. 2012;1(2):92\u2013100. https:\/\/doi.org\/10.4161\/jkst.19754.","journal-title":"Jakstat"},{"issue":"3","key":"7949_CR31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/01.res.0000054201.60308.1a","volume":"92","author":"L Calabresi","year":"2003","unstructured":"Calabresi L, Rossoni G, Gomaraschi M, et al. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-\u03b1 content and enhancing prostaglandin release. Circ Res. 2003;92(3):330\u20137. https:\/\/doi.org\/10.1161\/01.res.0000054201.60308.1a.","journal-title":"Circ Res"},{"issue":"10","key":"7949_CR32","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1161\/01.atv.0000091338.93223.e8","volume":"23","author":"A Kontush","year":"2003","unstructured":"Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003;23(10):1881\u20138. https:\/\/doi.org\/10.1161\/01.atv.0000091338.93223.e8.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"7949_CR33","doi-asserted-by":"publisher","first-page":"H31","DOI":"10.1152\/ajpheart.00521.2016","volume":"314","author":"KK Durham","year":"2018","unstructured":"Durham KK, Chathely KM, Mak KC, et al. HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner. Am J Physiol Heart Circ Physiol. 2018;314(1):H31\u201344. https:\/\/doi.org\/10.1152\/ajpheart.00521.2016.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"7949_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jacbts.2022.09.010","volume":"8","author":"Z Guo","year":"2023","unstructured":"Guo Z, Valenzuela Ripoll C, Picataggi A, et al. Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury. J Am Coll Cardiol Basic Trans Sci. 2023;8(3):340\u201355. https:\/\/doi.org\/10.1016\/j.jacbts.2022.09.010.","journal-title":"J Am Coll Cardiol Basic Trans Sci"},{"issue":"6","key":"7949_CR35","doi-asserted-by":"publisher","first-page":"H1447","DOI":"10.1152\/ajpheart.00432.2018","volume":"316","author":"KK Durham","year":"2019","unstructured":"Durham KK, Kluck G, Mak KC, Deng YD, Trigatti BL. Treatment with apolipoprotein A1 protects mice against doxorubicin-induced cardiotoxicity in a scavenger receptor class B, type I-dependent manner. Am J Physiol Heart Circ Physiol. 2019;316(6):H1447\u201357. https:\/\/doi.org\/10.1152\/ajpheart.00432.2018.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"12","key":"7949_CR36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1242\/dmm.016741","volume":"7","author":"K McCafferty","year":"2014","unstructured":"McCafferty K, Forbes S, Thiemermann C, Yaqoob MM. The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis Model Mech. 2014;7(12):1321\u201333. https:\/\/doi.org\/10.1242\/dmm.016741.","journal-title":"Dis Model Mech"},{"issue":"2","key":"7949_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/eurheartj\/ehz933","volume":"41","author":"N Cesarovic","year":"2020","unstructured":"Cesarovic N, Lipiski M, Falk V, Emmert MY. Animals in cardiovascular research. Eur Heart J. 2020;41(2):200\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehz933.","journal-title":"Eur Heart J"},{"issue":"10","key":"7949_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/eurheartj\/ehs411","volume":"34","author":"E Falk","year":"2013","unstructured":"Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists\u2019 view. Eur Heart J. 2013;34(10):719\u201328. https:\/\/doi.org\/10.1093\/eurheartj\/ehs411.","journal-title":"Eur Heart J"},{"issue":"38","key":"7949_CR39","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"issue":"3","key":"7949_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352\u201380. https:\/\/doi.org\/10.1002\/ejhf.2115.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"7949_CR41","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/eurjhf\/hft084","volume":"15","author":"PJ Patel","year":"2013","unstructured":"Patel PJ, Khera AV, Wilensky RL, Rader DJ. Anti-oxidative and cholesterol efflux capacities of high\u2010density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail. 2013;15(11):1215\u20139. https:\/\/doi.org\/10.1093\/eurjhf\/hft084.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"7949_CR42","doi-asserted-by":"publisher","first-page":"e019123","DOI":"10.1161\/jaha.120.019123","volume":"10","author":"JE Emmens","year":"2021","unstructured":"Emmens JE, Jia C, Ng LL, et al. Impaired high-density lipoprotein function in patients with heart failure. J Am Heart Assoc. 2021;10(9):e019123. https:\/\/doi.org\/10.1161\/jaha.120.019123.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"7949_CR43","doi-asserted-by":"publisher","first-page":"e004169","DOI":"10.1161\/JAHA.116.004169","volume":"5","author":"L Schrutka","year":"2016","unstructured":"Schrutka L, Distelmaier K, Hohensinner P, et al. Impaired high-density lipoprotein anti\u2010oxidative function is associated with outcome in patients with chronic heart failure. J Am Heart Assoc. 2016;5(12):e004169. https:\/\/doi.org\/10.1161\/JAHA.116.004169.","journal-title":"J Am Heart Assoc"},{"key":"7949_CR44","doi-asserted-by":"publisher","unstructured":"Abrahams C, Zhang W, Sangweni N, et al. Dysfunctional high-density lipoprotein particles are associated with cardiac alterations in cancer patients and tumor-bearing mice receiving doxorubicin. Basic Res Cardiol. 2026;121(1):129\u201344. https:\/\/doi.org\/10.1007\/s00395-025-01149-2.","DOI":"10.1007\/s00395-025-01149-2"},{"issue":"1","key":"7949_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacbts.2021.10.010","volume":"7","author":"EW Thompson","year":"2022","unstructured":"Thompson EW, Demissei BG, Smith AM, et al. Paraoxonase-1 Activity in breast cancer patients treated with doxorubicin with or without trastuzumab. J Am Coll Cardiol Basic Trans Sci. 2022;7(1):1\u201310. https:\/\/doi.org\/10.1016\/j.jacbts.2021.10.010.","journal-title":"J Am Coll Cardiol Basic Trans Sci"},{"key":"7949_CR46","volume-title":"Handb Exp Pharmacol","author":"A Kontush","year":"2015","unstructured":"Kontush A, Lindahl M, Lhomme M. Structure of HDL: particle subclasses and molecular components. In: Handb Exp Pharmacol. Cham, Heidelberg, New York, Dordrecht and London: Springer; 2015."},{"issue":"2","key":"7949_CR47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11010-021-04304-0","volume":"477","author":"H Thakkar","year":"2022","unstructured":"Thakkar H, Vincent V, Roy A, et al. Determinants of high-density lipoprotein (HDL) functions beyond proteome in Asian Indians: exploring the fatty acid profile of HDL phospholipids. Mol Cell Biochem. 2022;477(2):559\u201370. https:\/\/doi.org\/10.1007\/s11010-021-04304-0.","journal-title":"Mol Cell Biochem"},{"issue":"12","key":"7949_CR48","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1021\/acs.jproteome.5b00730","volume":"14","author":"S Krishnan","year":"2015","unstructured":"Krishnan S, Huang J, Lee H, et al. Combined high-density lipoprotein proteomic and glycomic profiles in patients at risk for coronary artery disease. J Proteome Res. 2015;14(12):5109\u201318. https:\/\/doi.org\/10.1021\/acs.jproteome.5b00730.","journal-title":"J Proteome Res"},{"issue":"3","key":"7949_CR49","doi-asserted-by":"publisher","first-page":"mjac004","DOI":"10.1093\/jmcb\/mjac004","volume":"14","author":"D Wang","year":"2022","unstructured":"Wang D, Yu B, Li Q, et al. HDL quality features revealed by proteome\u2013lipidome connectivity are associated with atherosclerotic disease. J Mol Cell Biol. 2022;14(3):mjac004. https:\/\/doi.org\/10.1093\/jmcb\/mjac004.","journal-title":"J Mol Cell Biol"},{"issue":"2","key":"7949_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacl.2019.01.002","volume":"13","author":"T Okada","year":"2019","unstructured":"Okada T, Ohama T, Takafuji K, et al. Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency. J Clin Lipidol. 2019;13(2):317\u201325. https:\/\/doi.org\/10.1016\/j.jacl.2019.01.002.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"7949_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/circulationaha.105.591743","volume":"113","author":"A Kawakami","year":"2006","unstructured":"Kawakami A, Aikawa M, Libby P, et al. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006;113(5):691\u2013700. https:\/\/doi.org\/10.1161\/circulationaha.105.591743.","journal-title":"Circulation"},{"issue":"9","key":"7949_CR52","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1194\/jlr.M077925","volume":"58","author":"E Zvintzou","year":"2017","unstructured":"Zvintzou E, Lhomme M, Chasapi S, et al. Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity. J Lipid Res. 2017;58(9):1869\u201383. https:\/\/doi.org\/10.1194\/jlr.M077925.","journal-title":"J Lipid Res"},{"issue":"5","key":"7949_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098368","volume":"9","author":"L-r Yan","year":"2014","unstructured":"Yan L-r, Wang D-x, Liu H, et al. A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labelling-based proteomic approach. PLoS One. 2014;9(5):e98368. https:\/\/doi.org\/10.1371\/journal.pone.0098368.","journal-title":"PLoS One"},{"issue":"3","key":"7949_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbalip.2011.07.013","volume":"1821","author":"K Alwaili","year":"2012","unstructured":"Alwaili K, Bailey D, Awan Z, et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochimica et Biophysica Acta (BBA). 2012;1821(3):405\u201315. https:\/\/doi.org\/10.1016\/j.bbalip.2011.07.013.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"7949_CR55","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1038\/s41467-018-05806-0","volume":"9","author":"XR Xu","year":"2018","unstructured":"Xu XR, Wang Y, Adili R, et al. Apolipoprotein A-IV binds \u03b1IIb\u03b23 integrin and inhibits thrombosis. Nat Commun. 2018;9(1):3608. https:\/\/doi.org\/10.1038\/s41467-018-05806-0.","journal-title":"Nat Commun"},{"issue":"4","key":"7949_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094264","volume":"9","author":"Y Tan","year":"2014","unstructured":"Tan Y, Liu TR, Hu SW, et al. Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions. PLoS One. 2014;9(4):e94264. https:\/\/doi.org\/10.1371\/journal.pone.0094264.","journal-title":"PLoS One"},{"key":"7949_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118565","volume":"397","author":"T Vaisar","year":"2024","unstructured":"Vaisar T, Babenko I, Horvath KV, Niisuke K, Asztalos BF. Relationships between HDL subpopulation proteome and HDL function in overweight\/obese people with and without coronary heart disease. Atherosclerosis. 2024;397:118565. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118565.","journal-title":"Atherosclerosis"},{"key":"7949_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jprot.2014.04.010","volume":"106","author":"I Jorge","year":"2014","unstructured":"Jorge I, Burillo E, Mesa R, et al. The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture. J Proteom. 2014;106:61\u201373. https:\/\/doi.org\/10.1016\/j.jprot.2014.04.010.","journal-title":"J Proteom"},{"issue":"5","key":"7949_CR59","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/mol.0000000000000702","volume":"31","author":"A Zheng","year":"2020","unstructured":"Zheng A, Widmann C. The interplay between serum amyloid A and HDLs. Curr Opin Lipidol. 2020;31(5):300\u20131. https:\/\/doi.org\/10.1097\/mol.0000000000000702.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"7949_CR60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00125-004-1654-6","volume":"48","author":"C Poitou","year":"2005","unstructured":"Poitou C, Viguerie N, Cancello R, et al. Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia. 2005;48(3):519\u201328. https:\/\/doi.org\/10.1007\/s00125-004-1654-6.","journal-title":"Diabetologia"},{"issue":"2","key":"7949_CR61","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.amjcard.2005.03.054","volume":"96","author":"C Tsioufis","year":"2005","unstructured":"Tsioufis C, Stougiannos P, Kakkavas A, et al. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol. 2005;96(2):252\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2005.03.054.","journal-title":"Am J Cardiol"},{"issue":"3","key":"7949_CR62","doi-asserted-by":"publisher","first-page":"e0121947","DOI":"10.1371\/journal.pone.0121947","volume":"10","author":"A Erdembileg","year":"2015","unstructured":"Erdembileg A, Mirsoian A, Enkhmaa B, et al. Attenuated age-impact on systemic inflammatory markers in the presence of a metabolic burden. PLoS ONE. 2015;10(3):e0121947. https:\/\/doi.org\/10.1371\/journal.pone.0121947.","journal-title":"PLoS ONE"},{"key":"7949_CR63","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijcard.2016.09.116","volume":"225","author":"Y Miyazaki","year":"2016","unstructured":"Miyazaki Y, Katanasaka Y, Sunagawa Y, et al. Effect of statins on atherogenic serum amyloid A and \u03b11-antitrypsin low-density lipoprotein complexes. Int J Cardiol. 2016;225:332\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.116.","journal-title":"Int J Cardiol"},{"issue":"2","key":"7949_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10557-008-6158-z","volume":"23","author":"NM Pires","year":"2009","unstructured":"Pires NM, Jukema JW. Early systemic inflammatory response to drug-eluting stents implantation: the heart of the difference? Editorial to: Comparison of changes in early inflammatory markers between sirolimus- and paclitaxel-eluting stent implantation by Li et al. Cardiovasc Drugs Ther. 2009;23(2):103\u20135. https:\/\/doi.org\/10.1007\/s10557-008-6158-z.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7949_CR65","doi-asserted-by":"publisher","first-page":"1197432","DOI":"10.3389\/fcvm.2023.1197432","volume":"10","author":"LJ den Hartigh","year":"2023","unstructured":"den Hartigh LJ, May KS, Zhang XS, Chait A, Blaser MJ. Serum amyloid A and metabolic disease: evidence for a critical role in chronic inflammatory conditions. Front Cardiovasc Med. 2023;10:1197432. https:\/\/doi.org\/10.3389\/fcvm.2023.1197432.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"7949_CR66","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/nejm199408183310701","volume":"331","author":"G Liuzzo","year":"1994","unstructured":"Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417\u201324. https:\/\/doi.org\/10.1056\/nejm199408183310701.","journal-title":"N Engl J Med"},{"issue":"12","key":"7949_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100307","volume":"63","author":"M Holzer","year":"2022","unstructured":"Holzer M, Ljubojevic-Holzer S, Souza Junior DR, et al. HDL isolated by immunoaffinity, ultracentrifugation, or precipitation is compositionally and functionally distinct. J Lipid Res. 2022;63(12):100307. https:\/\/doi.org\/10.1016\/j.jlr.2022.100307.","journal-title":"J Lipid Res"},{"issue":"9","key":"7949_CR68","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14789450.2019.1650645","volume":"16","author":"GE Ronsein","year":"2019","unstructured":"Ronsein GE, Vaisar T. Deepening our understanding of HDL proteome. Expert Rev Proteom. 2019;16(9):749\u2013. https:\/\/doi.org\/10.1080\/14789450.2019.1650645. 60.","journal-title":"Expert Rev Proteom"},{"issue":"5","key":"7949_CR69","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1021\/pr5011586","volume":"14","author":"J Marsillach","year":"2015","unstructured":"Marsillach J, Becker JO, Vaisar T, et al. Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis. J Proteome Res. 2015;14(5):2046\u201354. https:\/\/doi.org\/10.1021\/pr5011586.","journal-title":"J Proteome Res"},{"key":"7949_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100135","author":"B Shao","year":"2021","unstructured":"Shao B, Mathew AV, Thornock C, et al. Altered HDL proteome predicts incident CVD in chronic kidney disease patients. J Lipid Res. 2021. https:\/\/doi.org\/10.1016\/j.jlr.2021.100135.","journal-title":"J Lipid Res"},{"issue":"Supplement1","key":"7949_CR71","doi-asserted-by":"publisher","first-page":"cvag092","DOI":"10.1093\/cvr\/cvag092.071","volume":"122","author":"G Giron Martinez","year":"2026","unstructured":"Giron Martinez G, Padro T, Guala A, et al. HDL structural and compositional alterations in type 2 diabetes mellitus patients: identifying potential biomarkers for subclinical atherosclerosis detection and disease progression. Cardiovasc Res. 2026;122(Supplement1):cvag092. https:\/\/doi.org\/10.1093\/cvr\/cvag092.071.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"7949_CR72","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.1101","volume":"20","author":"JE Emmens","year":"2018","unstructured":"Emmens JE, Jones DJ, Cao TH, et al. Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. Eur J Heart Fail. 2018;20(2):260\u20137. https:\/\/doi.org\/10.1002\/ejhf.1101.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"7949_CR73","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/S0022-2275(20)39113-6","volume":"37","author":"N Fournier","year":"1996","unstructured":"Fournier N, de la Llera Moya M, Burkey B, et al. Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res. 1996;37(8):1704\u201311. https:\/\/doi.org\/10.1016\/S0022-2275(20)39113-6.","journal-title":"J Lipid Res"},{"issue":"9","key":"7949_CR74","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.3390\/ijms22094908","volume":"22","author":"T Paavola","year":"2021","unstructured":"Paavola T, Bergmann U, Kuusisto S, et al. Distinct fatty acid compositions of hdl phospholipids are characteristic of metabolic syndrome and premature coronary heart disease\u2014Family study. Int J Mol Sci. 2021;22(9):4908. https:\/\/doi.org\/10.3390\/ijms22094908.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"7949_CR75","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.bbalip.2015.05.007","volume":"1851","author":"F Rached","year":"2015","unstructured":"Rached F, Lhomme M, Camont L, et al. Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. Biochim Biophys Acta Mol Cell Biol Lipids. 2015;1851(9):1254\u201361. https:\/\/doi.org\/10.1016\/j.bbalip.2015.05.007.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"11","key":"7949_CR76","doi-asserted-by":"publisher","first-page":"e011792","DOI":"10.1161\/jaha.118.011792","volume":"8","author":"PJ Meikle","year":"2019","unstructured":"Meikle PJ, Formosa MF, Mellett NA, et al. HDL phospholipids, but not cholesterol distinguish acute coronary syndrome from stable coronary artery disease. J Am Heart Assoc. 2019;8(11):e011792. https:\/\/doi.org\/10.1161\/jaha.118.011792.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"7949_CR77","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.atherosclerosis.2015.05.037","volume":"241","author":"I Sutter","year":"2015","unstructured":"Sutter I, Velagapudi S, Othman A, et al. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis. 2015;241(2):539\u201346. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.05.037.","journal-title":"Atherosclerosis"},{"issue":"2","key":"7949_CR78","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbrc.2018.01.062","volume":"496","author":"SC Sherratt","year":"2018","unstructured":"Sherratt SC, Mason RP. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2018.01.062.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"7949_CR79","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.numecd.2013.12.011","volume":"24","author":"C Morgantini","year":"2014","unstructured":"Morgantini C, Meriwether D, Baldi S, et al. HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis. 2014;24(6):594\u20139. https:\/\/doi.org\/10.1016\/j.numecd.2013.12.011.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"7949_CR80","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jacl.2017.06.018","volume":"11","author":"W Hancock-Cerutti","year":"2017","unstructured":"Hancock-Cerutti W, Lhomme M, Dauteuille C, et al. Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. J Clin Lipidol. 2017;11(5):1192\u2013200. https:\/\/doi.org\/10.1016\/j.jacl.2017.06.018. e3.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"7949_CR81","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1476-511x-10-70","volume":"10","author":"KM Argraves","year":"2011","unstructured":"Argraves KM, Sethi AA, Gazzolo PJ, et al. S1P, dihydro-S1P and C24: 1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011;10(1):70. https:\/\/doi.org\/10.1186\/1476-511x-10-70.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"7949_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02624-9","volume":"24","author":"W Le Goff","year":"2025","unstructured":"Le Goff W, Bourron O, Materne C, et al. Inverse relationship between circulating sphingosine-1-phosphate and precursor species and coronary artery calcification score in type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):85. https:\/\/doi.org\/10.1186\/s12933-025-02624-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"7949_CR83","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S0022-2275(20)32402-0","volume":"41","author":"JS Parks","year":"2000","unstructured":"Parks JS, Huggins KW, Gebre AK, Burleson ER. Phosphatidylcholine fluidity and structure affect lecithin:cholesterol acyltransferase activity. J Lipid Res. 2000;41(4):546\u201353.","journal-title":"J Lipid Res"},{"key":"7949_CR84","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.06.441","volume":"355","author":"M Taradeh","year":"2022","unstructured":"Taradeh M, Dahik V, Lhomme M, et al. Enrichment of high-density lipoproteins with phosphatidylethanolamine (36: 5) impairs their protective biological activities and is associated with atherosclerosis in women. Atherosclerosis. 2022;355:72. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.441.","journal-title":"Atherosclerosis"},{"issue":"7","key":"7949_CR85","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1194\/jlr.M300062-JLR200","volume":"44","author":"JW Burgess","year":"2003","unstructured":"Burgess JW, Boucher J, Neville TA, et al. Phosphatidylinositol promotes cholesterol transport and excretion. J Lipid Res. 2003;44(7):1355\u201363. https:\/\/doi.org\/10.1194\/jlr.M300062-JLR200.","journal-title":"J Lipid Res"},{"issue":"2","key":"7949_CR86","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/cvr\/cvp070","volume":"82","author":"K Sattler","year":"2009","unstructured":"Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82(2):201\u201311.","journal-title":"Cardiovasc Res"},{"key":"7949_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081097","author":"K Georgila","year":"2019","unstructured":"Georgila K, Vyrla D, Drakos E. Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11081097.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"7949_CR88","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1172\/jci118345","volume":"96","author":"BJ Van Lenten","year":"1995","unstructured":"Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96(6):2758\u201367. https:\/\/doi.org\/10.1172\/jci118345.","journal-title":"J Clin Invest"},{"issue":"1","key":"7949_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2007.10.007","volume":"199","author":"KR Feingold","year":"2008","unstructured":"Feingold KR, Shigenaga JK, Chui LG, et al. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis. 2008;199(1):19\u201326. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.10.007.","journal-title":"Atherosclerosis"},{"issue":"8","key":"7949_CR90","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1161\/01.ATV.0000227472.70734.ad","volume":"26","author":"CY Han","year":"2006","unstructured":"Han CY, Chiba T, Campbell JS, et al. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol. 2006;26(8):1806\u201313. https:\/\/doi.org\/10.1161\/01.ATV.0000227472.70734.ad.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"7949_CR91","doi-asserted-by":"publisher","first-page":"9613","DOI":"10.1073\/pnas.1103187108","volume":"108","author":"C Christoffersen","year":"2011","unstructured":"Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011;108(23):9613\u20138. https:\/\/doi.org\/10.1073\/pnas.1103187108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"7949_CR92","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00395-010-0112-5","volume":"105","author":"KJ Sattler","year":"2010","unstructured":"Sattler KJ, Elbasan \u015e, Keul P, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol. 2010;105(6):821\u201332. https:\/\/doi.org\/10.1007\/s00395-010-0112-5.","journal-title":"Basic Res Cardiol"},{"issue":"21","key":"7949_CR93","doi-asserted-by":"publisher","first-page":"9644","DOI":"10.1016\/S0021-9258(18)67562-3","volume":"261","author":"GA Coetzee","year":"1986","unstructured":"Coetzee GA, Strachan AF, van der Westhuyzen DR, et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem. 1986;261(21):9644\u201351. https:\/\/doi.org\/10.1016\/S0021-9258(18)67562-3.","journal-title":"J Biol Chem"},{"issue":"1","key":"7949_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39846-3","volume":"9","author":"M Schuchardt","year":"2019","unstructured":"Schuchardt M, Pr\u00fcfer N, Tu Y, et al. Dysfunctional high-density lipoprotein activates toll-like receptors via serum amyloid A in vascular smooth muscle cells. Sci Rep. 2019;9(1):3421. https:\/\/doi.org\/10.1038\/s41598-019-39846-3.","journal-title":"Sci Rep"},{"issue":"7","key":"7949_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9070805","volume":"9","author":"L Schoch","year":"2021","unstructured":"Schoch L, Badimon L, Vilahur G. Unraveling the complexity of HDL remodeling: on the hunt to restore HDL quality. Biomedicines. 2021;9(7):805. https:\/\/doi.org\/10.3390\/biomedicines9070805.","journal-title":"Biomedicines"},{"issue":"16","key":"7949_CR96","doi-asserted-by":"publisher","first-page":"10408","DOI":"10.1074\/jbc.M710474200","volume":"283","author":"MZ Ashraf","year":"2008","unstructured":"Ashraf MZ, Kar NS, Chen X, et al. Specific oxidized phospholipids inhibit scavenger receptor bi-mediated selective uptake of cholesteryl esters. J Biol Chem. 2008;283(16):10408\u201314. https:\/\/doi.org\/10.1074\/jbc.M710474200.","journal-title":"J Biol Chem"},{"issue":"10","key":"7949_CR97","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1074\/jbc.RA118.005663","volume":"294","author":"A Witkowski","year":"2019","unstructured":"Witkowski A, Carta S, Lu R, et al. Oxidation of methionine residues in human apolipoprotein A-I generates a potent pro-inflammatory molecule. J Biol Chem. 2019;294(10):3634\u201346. https:\/\/doi.org\/10.1074\/jbc.RA118.005663.","journal-title":"J Biol Chem"},{"issue":"3","key":"7949_CR98","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00125-006-0574-z","volume":"50","author":"E Nobecourt","year":"2007","unstructured":"Nobecourt E, Davies MJ, Brown BE, et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia. 2007;50(3):643\u201353. https:\/\/doi.org\/10.1007\/s00125-006-0574-z.","journal-title":"Diabetologia"},{"issue":"8","key":"7949_CR99","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1007\/s00125-007-0718-9","volume":"50","author":"A Hoang","year":"2007","unstructured":"Hoang A, Murphy A, Coughlan M, et al. Advanced glycation of apolipoprotein AI impairs its anti-atherogenic properties. Diabetologia. 2007;50(8):1770\u20139. https:\/\/doi.org\/10.1007\/s00125-007-0718-9.","journal-title":"Diabetologia"},{"issue":"5","key":"7949_CR100","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2047487318816495","volume":"26","author":"H Riaz","year":"2019","unstructured":"Riaz H, Khan SU, Rahman H, et al. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2019;26(5):533\u201343. https:\/\/doi.org\/10.1177\/2047487318816495.","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"7949_CR101","doi-asserted-by":"publisher","first-page":"708","DOI":"10.5551\/jat.17210","volume":"20","author":"M Miyamoto-Sasaki","year":"2013","unstructured":"Miyamoto-Sasaki M, Yasuda T, Monguchi T, et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb. 2013;20(9):708\u201316. https:\/\/doi.org\/10.5551\/jat.17210.","journal-title":"J Atheroscler Thromb"},{"issue":"22","key":"7949_CR102","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1161\/01.Cir.0000103624.14436.4b","volume":"108","author":"BJ Ansell","year":"2003","unstructured":"Ansell BJ, Navab M, Hama S, et al. Inflammatory\/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108(22):2751\u20136. https:\/\/doi.org\/10.1161\/01.Cir.0000103624.14436.4b.","journal-title":"Circulation"},{"issue":"4","key":"7949_CR103","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1995-7645(10)60075-2","volume":"3","author":"A Kumar","year":"2010","unstructured":"Kumar A. Effect of simvastatin on paraoxonase 1 (PON1) activity and oxidative stress. Asian Pac J Trop Med. 2010;3(4):310\u20134. https:\/\/doi.org\/10.1016\/S1995-7645(10)60075-2.","journal-title":"Asian Pac J Trop Med"},{"issue":"27","key":"7949_CR104","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/eurheartj\/ehu105","volume":"35","author":"KK Ray","year":"2014","unstructured":"Ray KK, Ditmarsch M, Kallend D, et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J. 2014;35(27):1792\u2013800. https:\/\/doi.org\/10.1093\/eurheartj\/ehu105.","journal-title":"Eur Heart J"},{"issue":"2","key":"7949_CR105","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/atvbaha.108.179416","volume":"29","author":"G Catalano","year":"2009","unstructured":"Catalano G, Julia Z, Frisdal E, et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol. 2009;29(2):268\u201375. https:\/\/doi.org\/10.1161\/atvbaha.108.179416.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"7949_CR106","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.atherosclerosis.2011.12.027","volume":"221","author":"N Bellanger","year":"2012","unstructured":"Bellanger N, Julia Z, Villard EF, et al. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis. 2012;221(1):160\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.12.027.","journal-title":"Atherosclerosis"},{"issue":"7","key":"7949_CR107","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/atvbaha.110.207142","volume":"30","author":"L Yvan-Charvet","year":"2010","unstructured":"Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30(7):1430\u20138. https:\/\/doi.org\/10.1161\/atvbaha.110.207142.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"7949_CR108","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/circulationaha.108.836346","volume":"121","author":"SA Sorrentino","year":"2010","unstructured":"Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121(1):110\u201322. https:\/\/doi.org\/10.1161\/circulationaha.108.836346.","journal-title":"Circulation"},{"issue":"2","key":"7949_CR109","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1172\/jci118118","volume":"96","author":"N Vu-Dac","year":"1995","unstructured":"Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995;96(2):741\u201350. https:\/\/doi.org\/10.1172\/jci118118.","journal-title":"J Clin Invest"},{"issue":"24","key":"7949_CR110","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1161\/circulationaha.116.025687","volume":"134","author":"C Michael Gibson","year":"2016","unstructured":"Michael Gibson C, Korjian S, Tricoci P, et al. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016;134(24):1918\u201330. https:\/\/doi.org\/10.1161\/circulationaha.116.025687.","journal-title":"Circulation"},{"issue":"15","key":"7949_CR111","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","volume":"297","author":"JC Tardif","year":"2007","unstructured":"Tardif JC, Gr\u00e9goire J, L\u2019Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297(15):1675\u201382. https:\/\/doi.org\/10.1001\/jama.297.15.jpc70004.","journal-title":"JAMA"},{"issue":"17","key":"7949_CR112","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJMoa2400969","volume":"390","author":"CM Gibson","year":"2024","unstructured":"Gibson CM, Duffy D, Korjian S, et al. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med. 2024;390(17):1560\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2400969.","journal-title":"N Engl J Med"},{"issue":"47","key":"7949_CR113","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1093\/eurheartj\/ehae614","volume":"45","author":"CM Gibson","year":"2024","unstructured":"Gibson CM, Duffy D, Bahit MC, et al. Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial. Eur Heart J. 2024;45(47):5023\u201338. https:\/\/doi.org\/10.1093\/eurheartj\/ehae614.","journal-title":"Eur Heart J"},{"issue":"1","key":"7949_CR114","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2013.10.018","volume":"232","author":"C Tardy","year":"2014","unstructured":"Tardy C, Goffinet M, Boubekeur N, et al. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 2014;232(1):110\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.10.018.","journal-title":"Atherosclerosis"},{"issue":"46","key":"7949_CR115","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","volume":"35","author":"JC Tardif","year":"2014","unstructured":"Tardif JC, Ballantyne CM, Barter P, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014;35(46):3277\u201386. https:\/\/doi.org\/10.1093\/eurheartj\/ehu171.","journal-title":"Eur Heart J"},{"issue":"6","key":"7949_CR116","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cts.12487","volume":"10","author":"RL Dunbar","year":"2017","unstructured":"Dunbar RL, Movva R, Bloedon LT, et al. Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. Clin Transl Sci. 2017;10(6):455\u201369. https:\/\/doi.org\/10.1111\/cts.12487.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"7949_CR117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/circresaha.115.306223","volume":"118","author":"RD Shamburek","year":"2016","unstructured":"Shamburek RD, Bakker-Arkema R, Shamburek AM, et al. Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study. Circ Res. 2016;118(1):73\u201382. https:\/\/doi.org\/10.1161\/circresaha.115.306223.","journal-title":"Circ Res"},{"issue":"3","key":"7949_CR118","doi-asserted-by":"publisher","first-page":"e0119664","DOI":"10.1371\/journal.pone.0119664","volume":"10","author":"M-C Brulhart-Meynet","year":"2015","unstructured":"Brulhart-Meynet M-C, Braunersreuther V, Brinck J, et al. Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury. PLoS ONE. 2015;10(3):e0119664. https:\/\/doi.org\/10.1371\/journal.pone.0119664.","journal-title":"PLoS ONE"},{"key":"7949_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081938","author":"W Fr\u0105k","year":"2022","unstructured":"Fr\u0105k W, Wojtasi\u0144ska A, Lisi\u0144ska W, et al. Pathophysiology of cardiovascular diseases: new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10081938.","journal-title":"Biomedicines"},{"issue":"25","key":"7949_CR120","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1409065.","journal-title":"N Engl J Med"},{"issue":"6","key":"7949_CR121","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/circresaha.123.323520","volume":"134","author":"H Lal","year":"2024","unstructured":"Lal H, Verma SK, Wang Y, Xie M, Young ME. Circadian Rhythms in Cardiovascular Metabolism. Circ Res. 2024;134(6):635\u201358. https:\/\/doi.org\/10.1161\/circresaha.123.323520.","journal-title":"Circ Res"},{"issue":"1","key":"7949_CR122","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/circresaha.116.308034","volume":"119","author":"CS McAlpine","year":"2016","unstructured":"McAlpine CS, Swirski FK. Circadian influence on metabolism and inflammation in atherosclerosis. Circ Res. 2016;119(1):131\u201341. https:\/\/doi.org\/10.1161\/circresaha.116.308034.","journal-title":"Circ Res"},{"issue":"7","key":"7949_CR123","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/s0891-5849(02)01436-3","volume":"34","author":"A bin Ali","year":"2003","unstructured":"bin Ali A, Zhang Q, Lim YK, et al. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic Biol Med. 2003;34(7):824\u20139. https:\/\/doi.org\/10.1016\/s0891-5849(02)01436-3.","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"7949_CR124","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1373\/clinchem.2004.032763","volume":"50","author":"DS Freedman","year":"2004","unstructured":"Freedman DS, Otvos JD, Jeyarajah EJ, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem. 2004;50(7):1189\u2013200. https:\/\/doi.org\/10.1373\/clinchem.2004.032763.","journal-title":"Clin Chem"},{"issue":"10","key":"7949_CR125","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.2337\/dc07-0030","volume":"30","author":"PH Groop","year":"2007","unstructured":"Groop PH, Thomas MC, Roseng\u00e5rd-B\u00e4rlund M, et al. HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. Diabetes Care. 2007;30(10):2706\u20137. https:\/\/doi.org\/10.2337\/dc07-0030.","journal-title":"Diabetes Care"},{"issue":"4","key":"7949_CR126","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","volume":"26","author":"EJ Jeyarajah","year":"2006","unstructured":"Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26(4):847\u2013. https:\/\/doi.org\/10.1016\/j.cll.2006.07.006. 70.","journal-title":"Clin Lab Med"},{"issue":"3","key":"7949_CR127","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.clinbiochem.2014.11.017","volume":"48","author":"SP Matyus","year":"2015","unstructured":"Matyus SP, Braun PJ, Wolak-Dinsmore J, et al. HDL particle number measured on the Vantera\u00ae, the first clinical NMR analyzer. Clin Biochem. 2015;48(3):148\u201355. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.11.017.","journal-title":"Clin Biochem"},{"issue":"5","key":"7949_CR128","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/mol.0000000000000948","volume":"35","author":"T Vaisar","year":"2024","unstructured":"Vaisar T, Heinecke J. Quantification of high-density lipoprotein particle number by proton nuclear magnetic resonance: don\u2019t believe the numbers. Curr Opin Lipidol. 2024;35(5):228\u201333. https:\/\/doi.org\/10.1097\/mol.0000000000000948.","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"7949_CR129","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10557-025-07744-8","volume":"40","author":"A Palani","year":"2026","unstructured":"Palani A, Patel S, Patel S, et al. GLP1-RA and SGLT2-i: implementation and insulin deescalation strategies. Cardiovasc Drugs Ther. 2026;40(2):779\u201393. https:\/\/doi.org\/10.1007\/s10557-025-07744-8.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"7949_CR130","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.126.328680","volume":"138","author":"GG Repetti","year":"2026","unstructured":"Repetti GG, Abel ED, Tontonoz P, Sallam T. Adipose tissue plasticity, lipoprotein metabolism, and cardiovascular risk: the emerging role of the GLP-1 axis. Circ Res. 2026;138(12):e328680. https:\/\/doi.org\/10.1161\/circresaha.126.328680.","journal-title":"Circ Res"},{"key":"7949_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/ph18081202","author":"N Cosentino","year":"2025","unstructured":"Cosentino N, Trombara F, De Metrio M, et al. Cardiovascular protection in coronary artery disease: mechanistic and clinical insights into SGLT2 inhibitors and GLP-1 receptor agonists. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18081202.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"7949_CR132","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","volume":"16","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16(1):42. https:\/\/doi.org\/10.1186\/s12933-017-0529-3.","journal-title":"Cardiovasc Diabetol"},{"key":"7949_CR133","doi-asserted-by":"publisher","first-page":"117955141986681","DOI":"10.1177\/1179551419866811","volume":"12","author":"Y Kamijo","year":"2019","unstructured":"Kamijo Y, Ishii H, Yamamoto T, et al. Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419866811. https:\/\/doi.org\/10.1177\/1179551419866811.","journal-title":"Clin Med Insights Endocrinol Diabetes"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07949-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07949-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07949-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:41:14Z","timestamp":1788421274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07949-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":133,"alternative-id":["7949"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07949-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}